Back

Benefit of upfront combination lipid-lowering therapy in statin-naïve acute coronary syndrome patients with intermediate admission LDL-C and Lp(a)-driven predicted monotherapy failure

31 August 2026 (12:15 - 13:00)
Organised by: Logo
Congress Presentation Part of: Acute coronary syndromes treatment optimisation Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Francisco Buendia Santiago

General University Hospital Santa Lucia, Cartagena (Spain)

4 More presentations in this session

Presentation thumbnail
Long-term beta-blocker therapy after revascularised acute coronary syndrome (ACS) with preserved ejection fraction: a multi-centre retrospective cohort study
Doctor J. Tan (Chiayi, TW)
Abstract
Presentation thumbnail
Upfront combination lipid-lowering therapy in acute coronary syndrome: a bayesian network meta-analysis of low-density lipoprotein cholesterol reduction and major adverse cardiovascular events
Mr P. Sanjayanthan Keerthi (Chennai, IN)
Abstract
Presentation thumbnail
Antithrombotic strategies in conservatively managed patients with spontaneous coronary artery dissection
Doctor D. Wussler (Basel, CH)
Abstract
Presentation thumbnail
Early intensive combination lipid-lowering therapy in statin-naïve acute coronary syndrome: real-world attainment of lipid targets and analysis of therapeutic gaps
Professor G. Tan (Shatin, HK)
Abstract

Access the full session

Session thumbnail
Acute coronary syndromes treatment optimisation

The Event

Event poster

ESC Congress 2026

31 August 2026 12:15 CET
You may be interested in
thumbnail
Congress Presentation
Impact of lipoprotein(a) as a residual risk on long-term cardiovascular outcomes in patients with acute coronary syndrome treated with statin
27 August 2021
thumbnail
Congress Presentation
Possible shifts in paradigms for lipid-lowering therapies in acute coronary syndrome patients: combination therapy from Day 1
2 September 2024
thumbnail
Congress Presentation
Beyond expectations: who achieves the greatest LDL-c decline?
24 April 2026
thumbnail
Congress Presentation
Monetary costs and LDL-C reduction from upfront combination lipid-lowering therapy with ezetimibe in an irish ACS cohort
4 April 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources